HLS Therapeutics Current Valuation vs. Cash Per Share
| HLS Stock | CAD 3.64 0.01 0.27% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.92 | 0.8791 |
|
|
For HLS Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HLS Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HLS Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HLS Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HLS Therapeutics over time as well as its relative position and ranking within its peers.
HLS |
HLS Therapeutics Cash Per Share vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining HLS Therapeutics's current stock value. Our valuation model uses many indicators to compare HLS Therapeutics value to that of its competitors to determine the firm's financial worth. HLS Therapeutics is rated # 2 in current valuation category among its peers. It also is rated # 2 in cash per share category among its peers . The ratio of Current Valuation to Cash Per Share for HLS Therapeutics is about 110,799,674 . At this time, HLS Therapeutics' Cash Per Share is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value HLS Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for HLS Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.HLS Current Valuation vs. Competition
HLS Therapeutics is rated # 2 in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 588.66 Million. HLS Therapeutics totals roughly 188.36 Million in current valuation claiming about 32% of equities under Health Care industry.
HLS Cash Per Share vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
HLS Therapeutics |
| = | 188.36 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
HLS Therapeutics |
| = | 1.70 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
HLS Cash Per Share Comparison
HLS Therapeutics is currently under evaluation in cash per share category among its peers.
HLS Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in HLS Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, HLS Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of HLS Therapeutics' change in net profit over the period of time. It can combine multiple indicators of HLS Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2.8 M | -2.7 M | |
| Operating Income | -10 M | -9.5 M | |
| Income Before Tax | -27.8 M | -26.4 M | |
| Total Other Income Expense Net | -9.1 M | -8.6 M | |
| Net Loss | -27.5 M | -26.2 M | |
| Income Tax Expense | -272 K | -258.4 K | |
| Net Loss | -27.5 M | -26.2 M | |
| Net Loss | -21.2 M | -22.3 M | |
| Net Interest Income | -8.4 M | -8.8 M | |
| Interest Income | 350 K | 207.1 K | |
| Change To Netincome | 4.1 M | 3.9 M | |
| Net Loss | (0.85) | (0.81) | |
| Income Quality | (0.57) | (0.60) | |
| Net Income Per E B T | 0.99 | 1.36 |
HLS Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on HLS Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of HLS Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the HLS Therapeutics' important profitability drivers and their relationship over time.
Use HLS Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.HLS Therapeutics Pair Trading
HLS Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your HLS Therapeutics position
In addition to having HLS Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Munis Funds Thematic Idea Now
Munis Funds
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. The Munis Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Munis Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in HLS Stock
To fully project HLS Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of HLS Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include HLS Therapeutics' income statement, its balance sheet, and the statement of cash flows.